PeptidePicker
MitochondrialClinical Trials

SS-31

Also known as: Elamipretide · Bendavia · MTP-131

A mitochondria-targeted tetrapeptide that stabilizes the inner membrane to halt age-related energy decline. In clinical trials for heart failure and rare mitochondrial diseases.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~4 hours

Typical Dose

0.25 mg/kg

Administration

Subcutaneous injection or IV

Mechanism of Action

Binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing oxidative stress at the source.

Key Research Areas

mitochondrialanti-agingcardiolipinenergyheart failure

Frequently Asked Questions

What is SS-31?
A mitochondria-targeted tetrapeptide that stabilizes the inner membrane to halt age-related energy decline. In clinical trials for heart failure and rare mitochondrial diseases.
How does SS-31 work?
Binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing oxidative stress at the source.
What is the recommended dosage for SS-31?
The typical research dosage is 0.25 mg/kg, administered via Subcutaneous injection or IV. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of SS-31?
The half-life of SS-31 is approximately ~4 hours. This affects dosing frequency and timing in research protocols.
Is SS-31 FDA approved?
SS-31 is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about SS-31 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Mitochondrial